Aesynt and Meyra Partner to Market Robotic Solutions in the Republics of Azerbaijan and Turkey

Aesynt, a leading provider of integrated pharmacy automation solutions for hospitals and health systems, today announced a new strategic partnership with Meyra to market robotic solutions for public hospitals’ sterile compounding in the Republics of Azerbaijan and Turkey.

Supporting safety in the sterile compounding process is important to the Republic of Turkey’s Ministry of Health, as evidenced by the recent unprecedented step to establish reimbursement for public hospitals that use IV robotics for chemotherapy sterile compounding at a rate of 120 Turkish Lira per patient dose (approximately $48 USD).

“The Ministry has realized the benefits of Aesynt’s IV automation oncology solutions since 2008 with over 20 units of Aesynt’s first-generation chemotherapy robot (CytoCare), and is now ready to upgrade to i.v.STATION ONCO, Aesynt’s second-generation, state-of-the-art oncology robot,” explained Akif Uzuncarsili, General Manager of Meyra. “We are very pleased to be able to offer Aesynt’s global leading robotic solutions to help our customers automate compounding processes to enhance workflow and reduce errors while improving safety in the production of IV admixtures, including its market-leading upgrades such as tamper-evident capping, automatic labeling, decreased size and weight, and increased speed/throughput.”

Aesynt’s robotic solutions, including i.v.STATIONTM, i.v.STATION ONCOTM and i.v.STATIONTM 2 for total parenteral nutrition (TPN) preparations, are designed to automate the sterile compounding of IV admixtures, helping hospitals to:

  • Support safe and efficient production of ready-to-administer IVs;
  • Reduce medication errors;
  • Increase medication throughput; and
  • Lower costs associated with IV compounding and dispensing.

“The manual compounding and dispensing of injectable medications is one of the highest risk, expensive and labor-intensive processes in the hospital pharmacy,” said Kraig McEwen, CEO of Aesynt. “Through our new partnership with Meyra, we are able to extend the safety, flexibility and cost benefits of IV automation to public healthcare systems in Turkey and Azerbaijan.”

Aesynt is the only company to offer automation solutions at every stage of medication delivery—from the medication distribution source to administration at the patient bedside—regardless of medication type or distribution model.


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.